

# Development of Mass-Production Technology for the Clinical Implementation of Innovative CAR-T Cell Therapy (A-SEEDS Co., Ltd.)



City	Year of Establishment	Founder
Matsumoto, Nagano	2020	Yozo Nakazawa

Partner VC	Latest round of Fundraising	Valuation
—	Seed	Non-Disclosure

- Business Plan  
A-SEEDS, an innovative biotech company sprouted from Shinshu University, is dedicated to pioneering advanced treatments for life-threatening cancers. Harnessing the potential of non-viral genetic engineering, our cutting-edge immune cell therapy opens up new horizons of hope for patients seeking effective and transformative solutions.
- Research Outline  
The objective of this project is to develop mass-production technology for CAR-T cell therapy, a novel approach to cancer treatment, utilizing non-viral gene editing methods. Our focus extends to establishing a manufacturing base in collaboration with pharmaceutical formulation development and manufacturing support companies, both domestically and globally. This foundation will support the conduct of international clinical trials and the pursuit of regulatory approvals.

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	PCA 2024 - 2025FY	JPY 79 million	—

Contact Information :  
tel : 81-263-31-5882  
e-mail: [kiyohito.tani@a-seeds.co.jp](mailto:kiyohito.tani@a-seeds.co.jp)

Website : <https://www.a-seeds.co.jp/en-home>